Copyright Reports & Markets. All rights reserved.

Global Novel Coronavirus (COVID-19) Vaccine Market 2020 by Company, Regions, Type and Application, Forecast to 2025

Request for Sample of this report
Buy now

1 Novel Coronavirus (COVID-19) Vaccine Market Overview

  • 1.1 Product Overview and Scope of Novel Coronavirus (COVID-19) Vaccine
  • 1.2 Classification of Novel Coronavirus (COVID-19) Vaccine by Type
    • 1.2.1 Global Novel Coronavirus (COVID-19) Vaccine Revenue by Type: 2015 VS 2019 VS 2025
    • 1.2.2 Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type in 2019
    • 1.2.3 DNA
    • 1.2.4 RNA
    • 1.2.5 Others
  • 1.3 Global Novel Coronavirus (COVID-19) Vaccine Market by Application
    • 1.3.1 Overview: Global Novel Coronavirus (COVID-19) Vaccine Revenue by Application: 2015 VS 2019 VS 2025
    • 1.3.2 Mild Symptom Patient
    • 1.3.3 Critically Ill Patient
  • 1.4 Global Novel Coronavirus (COVID-19) Vaccine Market by Regions
    • 1.4.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Regions: 2015 VS 2019 VS 2025
    • 1.4.2 Global Market Size of Novel Coronavirus (COVID-19) Vaccine (2015-2025)
    • 1.4.3 North America (USA, Canada and Mexico) Novel Coronavirus (COVID-19) Vaccine Status and Prospect (2015-2025)
    • 1.4.4 Europe (Germany, France, UK, Russia and Italy) Novel Coronavirus (COVID-19) Vaccine Status and Prospect (2015-2025)
    • 1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Novel Coronavirus (COVID-19) Vaccine Status and Prospect (2015-2025)
    • 1.4.6 South America (Brazil, Argentina, Colombia) Novel Coronavirus (COVID-19) Vaccine Status and Prospect (2015-2025)
    • 1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Novel Coronavirus (COVID-19) Vaccine Status and Prospect (2015-2025)
  • 1.5 COVID-19 Outbreak: Novel Coronavirus (COVID-19) Vaccine Industry Impact
    • 1.5.1 COVID-19 Potential Implications for the Novel Coronavirus (COVID-19) Vaccine
      • 1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Novel Coronavirus (COVID-19) Vaccine
      • 1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
      • 1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
      • 1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
    • 1.5.2 Opportunity Analysis in Covid-19 Crisis
    • 1.5.3 Market Risk and Restraints
    • 1.5.4 Market Driving Force

2 Company Profiles

  • 2.1 Inovio Pharmaceuticals
    • 2.1.1 Inovio Pharmaceuticals Details
    • 2.1.2 Inovio Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.1.3 Inovio Pharmaceuticals SWOT Analysis
    • 2.1.4 Inovio Pharmaceuticals Product and Services
    • 2.1.5 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.2 Altimmune
    • 2.2.1 Altimmune Details
    • 2.2.2 Altimmune Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.2.3 Altimmune SWOT Analysis
    • 2.2.4 Altimmune Product and Services
    • 2.2.5 Altimmune Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.3 Codagenix, Inc.
    • 2.3.1 Codagenix, Inc. Details
    • 2.3.2 Codagenix, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.3.3 Codagenix, Inc. SWOT Analysis
    • 2.3.4 Codagenix, Inc. Product and Services
    • 2.3.5 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.4 Takis Biotech (Evvivax)
    • 2.4.1 Takis Biotech (Evvivax) Details
    • 2.4.2 Takis Biotech (Evvivax) Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.4.3 Takis Biotech (Evvivax) SWOT Analysis
    • 2.4.4 Takis Biotech (Evvivax) Product and Services
    • 2.4.5 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.5 Janssen Pharmaceutical Companies
    • 2.5.1 Janssen Pharmaceutical Companies Details
    • 2.5.2 Janssen Pharmaceutical Companies Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.5.3 Janssen Pharmaceutical Companies SWOT Analysis
    • 2.5.4 Janssen Pharmaceutical Companies Product and Services
    • 2.5.5 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.6 Zydus Cadila
    • 2.6.1 Zydus Cadila Details
    • 2.6.2 Zydus Cadila Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.6.3 Zydus Cadila SWOT Analysis
    • 2.6.4 Zydus Cadila Product and Services
    • 2.6.5 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.7 CanSino Biologics
    • 2.7.1 CanSino Biologics Details
    • 2.7.2 CanSino Biologics Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.7.3 CanSino Biologics SWOT Analysis
    • 2.7.4 CanSino Biologics Product and Services
    • 2.7.5 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.8 Bravovax
    • 2.8.1 Bravovax Details
    • 2.8.2 Bravovax Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.8.3 Bravovax SWOT Analysis
    • 2.8.4 Bravovax Product and Services
    • 2.8.5 Bravovax Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.9 GeoVax, Inc.
    • 2.9.1 GeoVax, Inc. Details
    • 2.9.2 GeoVax, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.9.3 GeoVax, Inc. SWOT Analysis
    • 2.9.4 GeoVax, Inc. Product and Services
    • 2.9.5 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.10 Vaxart
    • 2.10.1 Vaxart Details
    • 2.10.2 Vaxart Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.10.3 Vaxart SWOT Analysis
    • 2.10.4 Vaxart Product and Services
    • 2.10.5 Vaxart Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.11 Generex
    • 2.11.1 Generex Details
    • 2.11.2 Generex Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.11.3 Generex SWOT Analysis
    • 2.11.4 Generex Product and Services
    • 2.11.5 Generex Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.12 Baylor
    • 2.12.1 Baylor Details
    • 2.12.2 Baylor Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.12.3 Baylor SWOT Analysis
    • 2.12.4 Baylor Product and Services
    • 2.12.5 Baylor Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.13 ExpreS2ion Biotechnologies ApS
    • 2.13.1 ExpreS2ion Biotechnologies ApS Details
    • 2.13.2 ExpreS2ion Biotechnologies ApS Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.13.3 ExpreS2ion Biotechnologies ApS SWOT Analysis
    • 2.13.4 ExpreS2ion Biotechnologies ApS Product and Services
    • 2.13.5 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.14 Moderna, Inc.
    • 2.14.1 Moderna, Inc. Details
    • 2.14.2 Moderna, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.14.3 Moderna, Inc. SWOT Analysis
    • 2.14.4 Moderna, Inc. Product and Services
    • 2.14.5 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.15 Novavax, Inc.
    • 2.15.1 Novavax, Inc. Details
    • 2.15.2 Novavax, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.15.3 Novavax, Inc. SWOT Analysis
    • 2.15.4 Novavax, Inc. Product and Services
    • 2.15.5 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.16 Vaxil Bio Ltd.
    • 2.16.1 Vaxil Bio Ltd. Details
    • 2.16.2 Vaxil Bio Ltd. Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.16.3 Vaxil Bio Ltd. SWOT Analysis
    • 2.16.4 Vaxil Bio Ltd. Product and Services
    • 2.16.5 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.17 Clover Biopharmaceuticals
    • 2.17.1 Clover Biopharmaceuticals Details
    • 2.17.2 Clover Biopharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.17.3 Clover Biopharmaceuticals SWOT Analysis
    • 2.17.4 Clover Biopharmaceuticals Product and Services
    • 2.17.5 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.18 iBio, Inc.
    • 2.18.1 iBio, Inc. Details
    • 2.18.2 iBio, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.18.3 iBio, Inc. SWOT Analysis
    • 2.18.4 iBio, Inc. Product and Services
    • 2.18.3 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.19 Sanofi Pasteur
    • 2.19.1 Sanofi Pasteur Details
    • 2.19.2 Sanofi Pasteur Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.19.3 Sanofi Pasteur SWOT Analysis
    • 2.19.4 Sanofi Pasteur Product and Services
    • 2.19.5 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.20 GSK
    • 2.20.1 GSK Details
    • 2.20.2 GSK Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.20.3 GSK SWOT Analysis
    • 2.20.4 GSK Product and Services
    • 2.20.5 GSK Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.21 Curevac
    • 2.21.1 Curevac Details
    • 2.21.2 Curevac Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.21.3 Curevac SWOT Analysis
    • 2.21.4 Curevac Product and Services
    • 2.21.5 Curevac Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.22 ImmunoPrecise
    • 2.22.1 ImmunoPrecise Details
    • 2.22.2 ImmunoPrecise Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.22.3 ImmunoPrecise SWOT Analysis
    • 2.22.4 ImmunoPrecise Product and Services
    • 2.22.5 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)

3 Market Competition, by Players

  • 3.1 Global Novel Coronavirus (COVID-19) Vaccine Revenue and Share by Players (2015-2020)
  • 3.2 Market Concentration Rate
    • 3.2.1 Top 5 Novel Coronavirus (COVID-19) Vaccine Players Market Share
    • 3.2.2 Top 10 Novel Coronavirus (COVID-19) Vaccine Players Market Share
  • 3.3 Market Competition Trend

4 Market Size by Regions

  • 4.1 Global Novel Coronavirus (COVID-19) Vaccine Revenue and Market Share by Regions
  • 4.2 North America Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
  • 4.3 Europe Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
  • 4.4 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
  • 4.5 South America Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
  • 4.6 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)

5 North America Novel Coronavirus (COVID-19) Vaccine Revenue by Countries

  • 5.1 North America Novel Coronavirus (COVID-19) Vaccine Revenue by Countries (2015-2020)
  • 5.2 USA Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
  • 5.3 Canada Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
  • 5.4 Mexico Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)

6 Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Countries

  • 6.1 Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Countries (2015-2020)
  • 6.2 Germany Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
  • 6.3 UK Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
  • 6.4 France Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
  • 6.5 Russia Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
  • 6.6 Italy Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)

7 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Countries

  • 7.1 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Countries (2015-2020)
  • 7.2 China Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
  • 7.3 Japan Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
  • 7.4 Korea Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
  • 7.5 India Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
  • 7.6 Southeast Asia Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)

8 South America Novel Coronavirus (COVID-19) Vaccine Revenue by Countries

  • 8.1 South America Novel Coronavirus (COVID-19) Vaccine Revenue by Countries (2015-2020)
  • 8.2 Brazil Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
  • 8.3 Argentina Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)

9 Middle East & Africa Revenue Novel Coronavirus (COVID-19) Vaccine by Countries

  • 9.1 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Countries (2015-2020)
  • 9.2 Saudi Arabia Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
  • 9.3 UAE Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
  • 9.4 Egypt Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
  • 9.5 South Africa Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)

10 Market Size Segment by Type

  • 10.1 Global Novel Coronavirus (COVID-19) Vaccine Revenue and Market Share by Type (2015-2020)
  • 10.2 Global Novel Coronavirus (COVID-19) Vaccine Market Forecast by Type (2019-2024)
  • 10.3 DNA Revenue Growth Rate (2015-2025)
  • 10.4 RNA Revenue Growth Rate (2015-2025)
  • 10.5 Others Revenue Growth Rate (2015-2025)

11 Global Novel Coronavirus (COVID-19) Vaccine Market Segment by Application

  • 11.1 Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2015-2020)
  • 11.2 Novel Coronavirus (COVID-19) Vaccine Market Forecast by Application (2019-2024)
  • 11.3 Mild Symptom Patient Revenue Growth (2015-2020)
  • 11.4 Critically Ill Patient Revenue Growth (2015-2020)

12 Global Novel Coronavirus (COVID-19) Vaccine Market Size Forecast (2021-2025)

  • 12.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size Forecast (2021-2025)
  • 12.2 Global Novel Coronavirus (COVID-19) Vaccine Market Forecast by Regions (2021-2025)
  • 12.3 North America Novel Coronavirus (COVID-19) Vaccine Revenue Market Forecast (2021-2025)
  • 12.4 Europe Novel Coronavirus (COVID-19) Vaccine Revenue Market Forecast (2021-2025)
  • 12.5 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue Market Forecast (2021-2025)
  • 12.6 South America Novel Coronavirus (COVID-19) Vaccine Revenue Market Forecast (2021-2025)
  • 12.7 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Revenue Market Forecast (2021-2025)

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Data Source
    • 14.3 Disclaimer

    Market Overview
    The Novel Coronavirus (COVID-19) Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

    The most likely (base case) scenario is that the global Novel Coronavirus (COVID-19) Vaccine sales will be xx in 2020 from Novel Coronavirus (COVID-19) Vaccine million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Novel Coronavirus (COVID-19) Vaccine market size is expected to grow at xx% or more annually for the next five years.

    This report also researches and evaluates the impact of Covid-19 outbreak on the Novel Coronavirus (COVID-19) Vaccine industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Novel Coronavirus (COVID-19) Vaccine and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

    Market segmentation
    Novel Coronavirus (COVID-19) Vaccine market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

    By Type, Novel Coronavirus (COVID-19) Vaccine market has been segmented into:
    DNA
    RNA
    Others

    By Application, Novel Coronavirus (COVID-19) Vaccine has been segmented into:
    Mild Symptom Patient
    Critically Ill Patient

    Regions and Countries Level Analysis
    Regional analysis is another highly comprehensive part of the research and analysis study of the global Novel Coronavirus (COVID-19) Vaccine market presented in the report. This section sheds light on the sales growth of different regional and country-level Novel Coronavirus (COVID-19) Vaccine markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Novel Coronavirus (COVID-19) Vaccine market.

    The report offers in-depth assessment of the growth and other aspects of the Novel Coronavirus (COVID-19) Vaccine market in important countries (regions), including:
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia and Italy)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
    South America (Brazil, Argentina, Colombia)
    Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

    Competitive Landscape and Novel Coronavirus (COVID-19) Vaccine Market Share Analysis
    Novel Coronavirus (COVID-19) Vaccine competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Novel Coronavirus (COVID-19) Vaccine sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Novel Coronavirus (COVID-19) Vaccine sales, revenue and market share for each player covered in this report.

    The major players covered in Novel Coronavirus (COVID-19) Vaccine are:
    Inovio Pharmaceuticals
    Altimmune
    Codagenix, Inc.
    Takis Biotech (Evvivax)
    Janssen Pharmaceutical Companies
    Zydus Cadila
    CanSino Biologics
    Bravovax
    GeoVax, Inc.
    Vaxart
    Generex
    Baylor
    ExpreS2ion Biotechnologies ApS
    Moderna, Inc.
    Novavax, Inc.
    Vaxil Bio Ltd.
    Clover Biopharmaceuticals
    iBio, Inc.
    Sanofi Pasteur
    GSK
    Curevac
    ImmunoPrecise
    Among other players domestic and global, Novel Coronavirus (COVID-19) Vaccine market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
    Buy now